Skip to main content

Effects of high-dose corticosteroids on post-traumatic inflammatory mediators

Inflammation Research volume 58, pages 891–897 (2009)Cite this article

Abstract

Objective

Plasma concentrations of inflammatory mediators are substantially increased in major orthopaedic surgery. It was our hypothesis that corticosteroids would reduce the post-operative levels of inflammatory mediators in patients with ankylosing spondylitis, and we performed a single-centre randomised controlled trial.

Patients and methods

In 20 consecutive patients, an osteotomy of the lumbar spine was done. By concealed random allocation, 10 of the patients were given 10 mg/kg of methylprednisolone pre-operatively. The control patients received the same amount of saline. Samples of arterial blood and local blood from the surgical site were sampled and analysed for inflammatory cytokines and prostaglandin E2.

Results

There were significant increments in systemic levels of IL-6, IL-10 and sTNF-R1. Corticosteroids significantly reduced the increases of IL-6 and significantly increased the levels of IL-10 and sTNF-R1. Locally, the expressions of TNF-α, IL-1β, IL-6 and sTNF-R1 were significantly increased in both groups post-operatively. Corticosteroids significantly increased the local expressions of IL-10 and sTNF-R1. There were significantly higher local than systemic levels of inflammatory mediators except for TNF-α.

Conclusion

This study shows that in traumatic injury there are generally higher local than systemic expressions of inflammatory mediators, and that the main anti-inflammatory effects of high-dose corticosteroids are suppression of systemic IL-6 and increased expressions of IL-10 and sTNF-R1, both systemically and locally.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;Suppl 3:iii8–iii18.

    Google Scholar 

  2. Keller C, Webb A, Davies J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis. 2003;62:1128–32.

    Article  PubMed  CAS  Google Scholar 

  3. Sonel B, Tutkak H, Duzgun N. Serum levels of Il-1 beta, TNF-alpha, Il-8, and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine. 2002;69:463–8.

    Article  PubMed  Google Scholar 

  4. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505.

    Article  PubMed  CAS  Google Scholar 

  5. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006;65:713–20.

    Article  PubMed  CAS  Google Scholar 

  6. Lange U, Teichmann J, Stracke H. Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res. 2000;5:507–11.

    PubMed  CAS  Google Scholar 

  7. Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol. 2003;132:158–62.

    Article  PubMed  CAS  Google Scholar 

  8. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology. 2005;44:1525–30.

    Article  PubMed  CAS  Google Scholar 

  9. Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006;54:1646–52.

    Article  PubMed  CAS  Google Scholar 

  10. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosisng spondylitis after treatment with infliximab. J Ann Rheum Dis. 2008;67:511–7.

    Article  CAS  Google Scholar 

  11. Schleimer RP. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol. 1993;45:S3–7.

    Article  PubMed  CAS  Google Scholar 

  12. Skjelbred P, Løkken P. Reduction of pain and swelling by a corticosteroid. Eur J Clin Pharmacol. 1982;21:391–6.

    Article  PubMed  CAS  Google Scholar 

  13. Holte K, Kehlet H. Perioperative single-dose glucocorticoid administration: pathophysiologic effects and clinical implications. J Am Coll Surg. 2002;195:694–712.

    Article  PubMed  Google Scholar 

  14. Bisgaard T, Klarskov B, Kehlet H, Rosenberg J. Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy. A randomized double-blind placebo-controlled trial. Ann Surg. 2003;238:651–60.

    Article  PubMed  Google Scholar 

  15. Lundin A, Magnuson A, Axelsson K, Kogler H, Samuelsson L. The effect of perioperative corticosteroids on the outcome of microscopic lumbar disc surgery. Eur Spine J. 2003;12:625–30.

    Article  PubMed  Google Scholar 

  16. Ferreira SH, Cunha FQ, Lorenzetti FB. Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br J Pharmacol. 1997;121:883–8.

    Article  PubMed  CAS  Google Scholar 

  17. Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after major surgery. Br J Surg. 1992;79(8):757–60.

    Article  PubMed  CAS  Google Scholar 

  18. Garret S, Jenkins T, Kennedy LG. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.

    Google Scholar 

  19. Calin A, Garret S, Whitelock H. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.

    PubMed  CAS  Google Scholar 

  20. Kennedy LG, Jenkinson TR, Mallorie PA, Whitelock HC, Barret SL, Calin A. Ankylosing spondylitis: the correlation between metrology score and radiology. Br J Rheumatol. 1995;34:767–71.

    Article  PubMed  CAS  Google Scholar 

  21. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304–15.

    PubMed  CAS  Google Scholar 

  22. Braun J, Bollow M, Seyrekbasan F, Häberle HJ, Eggens U, Mertz A, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol. 1996;23:659–64.

    PubMed  CAS  Google Scholar 

  23. af Klint E, Grundtman C, Engström M, Catrina AI, Makrygiannakis D, Klareskog L, et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum. 2009;52:3880–9.

    Article  CAS  Google Scholar 

  24. Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, Roberts-Thomson PJ. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum. 1997;40:1400–8.

    Article  PubMed  CAS  Google Scholar 

  25. Sauerland S, Nagelschmidt M, Mallmann P, Neugebeuer EA. Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review. Drug Saf. 2000;23:449–61.

    Article  PubMed  CAS  Google Scholar 

  26. Gilron I, Milne B, Hong M. Cyclooxygenase-2 inhibitors in postoperative pain management. Current evidence and future directions. Anesthesiology. 2003;99:1198–208.

    Article  PubMed  Google Scholar 

  27. Fereira SH, Lorenzetti BB, Poole S. Bradykinin initiates cytokine mediated inflammatory hyperalgesia. Br J Phamacol. 1993;110:127–31.

    Google Scholar 

  28. Baton BE, Jakaway JP, Smith SR, Siegel MI. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol. 1991;13:251–61.

    Article  Google Scholar 

  29. Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev. 2007;18:45–56.

    Article  PubMed  CAS  Google Scholar 

  30. Scheinman RI, Cogwell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;13(270):232–3.

    Google Scholar 

  31. Scheinman RI, Gualberto A, Jewll CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transpression of NF-kappa B by activated glucoid receptors. Cell Mol Biol. 1995;15:943–53.

    CAS  Google Scholar 

  32. Adcock IM, Shirasaki H, Gelder CM. The effect of glucocorticoids on phorbol ester and cytokine stimulated transcription factor activation in human lung. Life Sci. 1994;55:1147–53.

    Article  PubMed  CAS  Google Scholar 

  33. Barnes PJ, Karin M. Mechanism of disease: nuclear factor-[kappa]B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;15:1066–71.

    Article  Google Scholar 

  34. Krohn CD, Reikerås O, Aasen AO. The cytokines IL-1beta and IL-1 receptor antagonist, IL-2 and IL-2 soluble receptor-alpha, IL-6 and IL-6 soluble receptor, TNF-alpha and TNF soluble receptor I, and IL10 in drained and systemic blood after major orthopaedic surgery. Eur J Surg. 1999;165:101–9.

    Article  PubMed  CAS  Google Scholar 

  35. Clementsen T, Krohn CD, Reikerås O. Systemic and local cytokine patterns during total hip surgery. Scand J Clin Lab Invest. 2006;66:535–42.

    Article  PubMed  CAS  Google Scholar 

  36. Kotake S, Sato K, Kim KJ. Interleukin-6 and soluble interleukin-6 in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11:88–95.

    PubMed  CAS  Article  Google Scholar 

  37. Okamoto H, Yamamura M, Morita Y. The synovial expression and blood levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum. 1997;40:1096–105.

    Article  PubMed  CAS  Google Scholar 

  38. Steensberg A, Fischer CP, Keller C, Kirsten Møller, Pedersen BK. Il-6 enhances plasma Il-1ra, Il-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003;285:E433–7.

    PubMed  CAS  Google Scholar 

  39. Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol. 1990;20:2439–43.

    Article  PubMed  CAS  Google Scholar 

  40. Fantuzzi G, Ghezzi P. Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases. Mediators Inflamm. 1993;2:263–70.

    Article  PubMed  CAS  Google Scholar 

  41. Høgevold HE, Kierulf P, Ovstebø R, Reikerås O. Acute phase reactant and interleukin 6 after total hip replacement. Effects of high dose corticosteroids. Eur J Surg. 1992;158:339–45.

    PubMed  Google Scholar 

  42. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83:113–8.

    PubMed  CAS  Google Scholar 

  43. Sheeran P, Hall GM. Cytokines in anaesthesia. Br J Anaesth. 1997;78:201–19.

    PubMed  CAS  Google Scholar 

  44. Ayala A, Lehman DL, Herdon CD, Chaudry IH. Mechanism of enhanced susceptibility to sepsis following hemorrhage: interleukin-10 suppression of T-cell response is mediated by eicosanoid-induced interleukin-4 release. Arch Surg. 1994;129:1172–8.

    PubMed  CAS  Google Scholar 

  45. Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol. 1993;150:1999–2006.

    PubMed  CAS  Google Scholar 

  46. Dandona P, Aljada A, Garg R, Mohanty P. Increase in plasma Interleukin–10 following hydrocortisone injection. J Clin Endocinol Metab. 1999;84:1141–4.

    Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Orthopaedics, Rikshospitalet University Clinic, University of Oslo, 0027, Oslo, Norway

    Olav Reikerås & Jens Ivar Brox

  2. Department of Anaesthesiology, Rikshospitalet University Clinic, University of Oslo, 0027, Oslo, Norway

    Arthur Helle & Claus Danckert Krohn

Authors
  1. Olav Reikerås
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arthur Helle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claus Danckert Krohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jens Ivar Brox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olav Reikerås.

Additional information

Responsible Editor: A. Bauhofer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Reikerås, O., Helle, A., Krohn, C.D. et al. Effects of high-dose corticosteroids on post-traumatic inflammatory mediators. Inflamm. Res. 58, 891–897 (2009). https://doi.org/10.1007/s00011-009-0061-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-009-0061-3

Keywords

  • Ankylosing spondylitis
  • Inflammatory mediators
  • Local
  • Surgery
  • Systemic
  • Trauma